Results 101 to 110 of about 90,077 (217)

Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple‐Negative Breast Cancer to PD‐1 Blockade

Advanced Science, EarlyView.
This study identifies ARID3A as a key immunosuppressive transcription factor in TNBC. Its inhibition activates the type I IFN pathway, boosting CD8+ T cell infiltration and sensitizing tumors to anti‐PD‐1. The FDA‐approved migraine drug Rimegepant targets ARID3A, enhances immunotherapy efficacy in preclinical models, and establishes a druggable axis to
Teng Zhou, Yifei Zhu, Cheng Zeng, Jinlu Han, Huiying Huang, Doudou Li, Mingxi Lin, Yizi Jin, Qin Guo, Yuxin Yan, Xinhui Mao, Yifei Zhou, Jian Zhang   +12 more
wiley   +1 more source

Enhancing CAR‐T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF‐Mediated Angiogenesis

Advanced Science, EarlyView.
This study reveals that CAR‐T cells in solid tumors produce CCL5, which paradoxically induces VEGF and angiogenesis to promote tumor growth. Blocking CCL5/VEGF signaling—through gene knockout, or the CCR5 inhibitor maraviroc—significantly enhances the antitumor efficacy of CAR‑T therapy (the diagram was created in Biorender).
Shishuo Sun, Qihong Li, Bixi Wang, Gang Wang, Ying Xue, Yibing Liang, Chenhe Hu, Zhenyu Wang, Xiaoge Gao, Haiheng Xu, Jun Song, Hailong Li, Liantao Li, Xiaoxiao Liu, Patrick Ming‐Kuen Tang, Qing Zhang   +15 more
wiley   +1 more source

Research progress of biomarkers associated with efficacy of immune checkpoint blockade

Zhongguo aizheng zazhi, 2018
Cancer immunotherapy has been a novel and efficient cancer therapeutic strategy besides surgery, chemotherapy, radiotherapy and targeted therapy for its durable clinical benefit.
ZHAO Haiyun, JI Peng, LI Xiaoguang
doaj  

RBM10 Deficiency Promotes Anti‐PD‐1 Resistance in LUAD via STING Alternative Splicing‐Driven CCL7 Signaling and Macrophage Polarization

Advanced Science, EarlyView.
RBM10 deficiency promotes anti‐PD‐1 resistance in lung adenocarcinoma by altering STING alternative splicing, which enhances CCL7 secretion and CCR2‐dependent M2 macrophage polarization. A positive feedback loop via mitochondrial transfer sustains this immunosuppression.
Weitong Gao, Ruqiong Wang, Bo An, Lishuang Qi, Zihan Jing, Xingmei Ren, Yang Zhou, Mingjun Xu, Jiaojiao Li, Jie Liu, Liying Wang, Gang Xu, Rou Li, Dexin Jia, Yan Yu   +14 more
wiley   +1 more source

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

Advanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang, Xuan Wang, Xinfeng Dai, Linxin Tian, Wencheng Shen, Xueliang Liu, Wei Xue, Jiahua Pan, Yu Yang   +8 more
wiley   +1 more source

Humoral contributions to checkpoint blockade therapy. [PDF]

J Immunother Cancer
McKeague ML, Apostolidis SA.
europepmc   +1 more source

ROS Self‐Supply Nanoplatform Based on Fenton Catalyst for Chemodynamic and Immunotherapy: Reprogramming Cold Tumor Into Hot Tumor in Cancer Treatment

Advanced Science, EarlyView.
A multifunctional HA‐conjugated nanoplatform (HA‐PGMC) integrates CuO2, glucose oxidase, and mil‐100 to enable cascade catalytic ROS generation in tumor microenvironments. This self‐supplying ROS strategy induces immunogenic cell death, reprograms “cold” tumors into “hot” ones, and synergizes with PD‐L1 blockade, achieving potent chemodynamic ...
Man Lung Lee, Jack Chun Hin Chen, Wai Wing Cheng, Kwan Yee Lau, Hiu Yee Kwan, Ngar‐Yun Ellen Poon, Hung‐Wing Li   +6 more
wiley   +1 more source

Checkpoint blockade and the stem-like T cell trade-off. [PDF]

Mol Oncol
Mazet JM, Joyce JA.
europepmc   +1 more source

Harnessing MDM2‐Mediated Targeted Degradation of Transcriptional and Epigenetic Machinery to Disrupt Oncogenic Addictions in Pediatric Sarcoma

Advanced Science, EarlyView.
MDM2 dependency in pediatric sarcomas is driven by a novel p53‐independent oncogenic cistrome alongside canonical p53 pathway suppression. This study introduces MDM2‐recruiting transcriptional and epigenetic machinery degraders (MDM2‐TEMADs) as a novel precision oncology modality.
Jiawei Zhou, Xian Guan, Nan Li, Ying Zhang, Long Xie, Xingze Huang, Zhipeng Zhu, Zhuolin Ren, Xiaoyan Yu, Hanjun Guo, Yuanfang Wu, Lin Ma, Suya Zheng, Jingyao Zhang, Jiyang Liu, Victor Kuanmin Lee, Wenhao Chen, H. Phillip Koeffler, Jinhu Wang, Xin Han, Ye Chen, Liang Xu   +21 more
wiley   +1 more source

Broadening activity of checkpoint blockade agents by intratumoral nucleoside cleavage. [PDF]

JCI Insight
Rab R, Hong JS, Kinney BL, Schmitt NC, Parker WB, Westbrook A, Bennion KB, Ford ML, Weitzel DH, Miliani de Marval PL, Sorscher EJ, Ehrhardt A.   +11 more
europepmc   +1 more source